Skip to content
OpenCapital
Get started

Sutro Biopharma STRO Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
Regenxbio logo
RegenxbioRGNX
$15.23M-88.3%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$25.13M-15.9%
Xencor logo
XencorXNCR
$14.17M-64.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%—
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's cash & equivalents?
Sutro Biopharma (STRO) reported cash & equivalents of $73.68M in Q1 2026.
How has Sutro Biopharma's cash & equivalents changed year-over-year?
Sutro Biopharma's cash & equivalents decreased by 30.6% year-over-year, from $106.23M to $73.68M.
What is the long-term trend for Sutro Biopharma's cash & equivalents?
Over 5 years (2020 to 2025), Sutro Biopharma's cash & equivalents has grown at a -22.4% compound annual growth rate (CAGR), from $206.15M to $58.13M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.